| References: |
PF-4989216 significantly inhibits cell viability in SCLC cells with a PIK3CA mutation, such as NCI-H69, NCI-H1048, and Lu99A cells. PF-4989216, via PI3K signaling inhibition, blocks cell-cycle progression and reduces cell transformation in SCLCs. In SCLCs with PIK3CA mutation, PF-4989216 induces BIM-mediated apoptosis. In SCID mice bearing NCI-H69 or NCI-H1048 xenograft tumors, PF-4989216 (350 mg/kg, p.o.) inhibits PI3K phosphorylation signaling and induces antitumor activity. For the detailed information of PF-4989216, the solubility of PF-4989216 in water, the solubility of PF-4989216 in DMSO, the solubility of PF-4989216 in PBS buffer, the animal experiment (test) of PF-4989216, the cell expriment (test) of PF-4989216, the in vivo, in vitro and clinical trial test of PF-4989216, the EC50, IC50,and affinity,of PF-4989216, For the detailed information of PF-4989216, the solubility of PF-4989216 in water, the solubility of PF-4989216 in DMSO, the solubility of PF-4989216 in PBS buffer, the animal experiment (test) of PF-4989216, the cell expriment (test) of PF-4989216, the in vivo, in vitro and clinical trial test of PF-4989216, the EC50, IC50,and affinity,of PF-4989216, Please contact DC Chemicals. |
